Print
Email
Print Edition Stories
MHT's Julie Donnelly: Biotechs lag in social media use
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
Cubist Pharmaceuticals Inc. has met its safety objectives in a Phase 2 study of its treatment intended for prosthetic joint infections, the company announced today.
Cubicin (daptomycin for injection), Cubist’s therapy, treats skin and bloodstream infections related to Gram-positive bacteria, and the study employed it as a treatment in replacing infected prosthetic hip or knee joints following surgery.
Cubist (Nasdaq: CBST) officials noted the company’s objectives for the study – compare safety and tolerability of CUBICIN with current standards of treatment, including penicillin, teicoplanin or vancomycin. Results showed a similar number of adverse advents among the standard treatments.
In April, Cubist announced that it will no longer develop its drug ecallantide, a potential therapy to control bleeding in high-risk cardiac surgery patients.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
